Axalimogene Filolisbac

**Semantic type:** Pharmacologic Substance

**Definition:** A cancer vaccine containing a live-attenuated strain of the bacterium Listeria monocytogenes (Lm) encoding human papillomavirus (HPV) type 16 E7 fused to a non-hemolytic listeriolysin O protein with potential immunostimulatory and antineoplastic activities. Upon vaccination with axalimogene filolisbac, Listeria expresses the HPV 16 E7 antigen and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV 16 E7. This may result in tumor cell lysis. In addition, the Listeria vector itself may induce a potent immune response. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in the majority of cervical cancer cells.

**Synonyms:** - ADXS11-001 - ADXS11-001 Vaccine - AXALIMOGENE FILOLISBAC - Attenuated Live Listeria Encoding HPV 16 E7 Vaccine - Attenuated Live Listeria Encoding Human Papilloma Virus 16 E7 Vaccine - Lm-LLO-E7 - Lovaxin-C